Turning Point and Repare are left nursing heavy losses, while Relay just about weathers a storm.
The young biotech is well placed to deliver its first pivotal win, but investor focus might lie elsewhere.
Chemocentryx and Avadel will also see important FDA regulatory action this month, while Omeros gets another delay.
Data are due in the fourth quarter for Aldeyra, Aeglea and Radius, among other small developers.
Deciphera, Allakos and Uniqure are all set for important data disclosures.
The fourth quarter will see key immunotherapy data from Astrazeneca and Merck, while full details on Glaxo's anaemia pill, daprodustat, are expected.
Leap and Innate were clear winners on the stock market during the medical meeting, while Astrazeneca’s strong performance stands out among the large caps.
Here's a roundup of Vantage's coverage of the 2021 European Society for Medical Oncology congress.
Trodelvy has a chance to score in a study designed to expand its use, but given Gilead’s R&D track record nothing is certain.